Shanghai JMT-Bio Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS25
PHASE 3 / 2-315
RECRUITING10
READOUTS ≤12 MONTHS8
READOUT SLIPPED >6 MO8%
Delay Index: of 12 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Shanghai JMT-Bio Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| JMT101 Injection NCT06391944 |
P2 | Active, not recruiting | Local Advanced or Metastatic NSCLC; Harboring EGFR Common Mutation | 161 | 2023-05-17 |
| Recombinant Humanized Bispecific antibody against HER2,KN026 NCT05838066 |
P3 | Recruiting | First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer | 880 | 2025-07-31 |
| KN026/Placbo Injection NCT05427383 |
P2/3 | Recruiting | Stomach Cancer | 286 | 2025-11 |
| Mitoxantrone Hydrochloride Liposome NCT06892431 |
P2 | Not yet recruiting | Recurrent or Metastatic Nasopharyngeal Cancer; Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy | 150 | 2025-12-31 |
| JMT101 NCT06319313 |
P2/3 | Not yet recruiting | Squamous Cell Non-small Cell Lung Cancer | 534 | 2026-07-01 |
| phase Ib/Ⅱa st NCT07140809 |
P1/2 | Recruiting | Hypertriglyceridemia | 48 | 2026-07-31 (+2 mo) |
| JMT101 NCT06735391 |
P3 | Recruiting | Locally Advanced or Metastatic Non-squamous NSCLC; Harboring EGFR Sensitive Mutations NSCLC | 516 | 2026-09-30 |
| JSKN003 NCT06846437 |
P3 | Recruiting | Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants | 228 | 2026-10-13 |
| JMT108 NCT07280832 |
P1/2 | Recruiting | Unresectable Locally Advanced or Metastatic Melanoma; Unresectable Locally Advanced or Metastatic Urinary Tract Tumors | 500 | 2026-11-30 |
| Neo-Healer NCT06747338 |
P3 | Active, not recruiting | Early or Locally Advanced HER2-positive Breast Cancer | 520 | 2026-12-16 |
| JMT101 Injection NCT06380348 |
P3 | Not yet recruiting | Local Advanced or Metastatic NSCLC | 398 | 2027-03-26 |
| JMT601 Injection NCT07029139 |
P2 | Not yet recruiting | Primary Membranous Nephropathy | 156 | 2027-04-01 |
| JSKN003 NCT07545044 |
P2 | Not yet recruiting | HER2-positive Recurrent or Metastatic Breast Cancer | 60 | 2027-05-29 |
| JMT103 NCT06221072 |
P3 | Not yet recruiting | Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors | 1360 | 2027-05-31 |
| JMT101 NCT07134205 |
P3 | Not yet recruiting | Metastatic Colorectal Cancer (mCRC) | 252 | 2027-06-01 |
| JMT203 Injection NCT06868849 |
P1/2 | Recruiting | Non Small Cell Lung Cancer; Pancreatic Cancer | 307 | 2027-08-14 (+15 mo) |
| JSKN003 NCT07384377 |
P3 | Not yet recruiting | HER2-positive Colorectal Cancer | 123 | 2027-11-30 |
| Glumetinib NCT06829459 |
P3 | Recruiting | Non-Small Cell Lung Cancer | 350 | 2028-02-15 |
| JMT108 NCT06877650 |
P1/2 | Recruiting | Advanced Malignant Tumors | 436 | 2028-03-30 |
| Narlumosbart NCT05813665 |
P3 | Not yet recruiting | Giant Cell Tumor of Bone | 146 | 2028-06 |
| JSKN003 NCT06998771 |
P2 | Not yet recruiting | HER2-positive Gastric Cancer | 153 | 2028-06-30 |
| Glumetinib Tablets NCT06908772 |
P2/3 | Not yet recruiting | Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression | 390 | 2028-12-31 |
| SYS6090 + pemetrexed + platinum-based chemotherapy NCT07472647 |
P1/2 | Not yet recruiting | Non-Small Cell Lung Cancer; Small Cell Lung Cancer | 596 | 2029-02-28 |
| KN026 NCT07332533 |
P2/3 | Not yet recruiting | HER2-positive Gastric Cancer | 490 | 2032-06-30 |
| KN026 NCT07441460 |
P3 | Recruiting | Resectable HER2-positive Breast Cancer | 1800 | 2034-08-07 |